Institute for Research in Biomedicine

Immunoqure Ag

Humabs, LLC

Proteomedix Ag

Institute of Research in Biomedicine

Annalisa Macagno

Antonio Lanzavecchia

Adrian Hayday

Kai Krohn

Kai Kisand

Mike Rothe

Shimobi Onuoha

Paert Peterson

Martin Woodward

Syeda F Y Haque

Annamari Ranki

Edward Stuart

Part Peterson

Philip Vlaicu

Steffen Meyer

Ralph Schiess

Antonia Lanzavecchia

Alcibiade Athanasiou

Thomas Steuber

Kathrin Endt

Syeda F Haque

Pärt Peterson

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-α antibodies

A method for collecting information about the health status of a subject is proposed involving the quantitative detection, in serum, plasma or blood of the subject, of the concentration of THBS1, the proportion of free PSA (% fPSA), preferably including the concentration of at least one protein selected from the group consisting of CTSD, OLFM4, ICAM1.

Method of detecting proteins in human samples and uses of such methods

Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-&#x3b1; antibodies as well as IFN-&#x3b1; binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-&#x3b1; antibodies

The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

Human cytomegalovirus neutralizing antibodies and use thereof

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.

Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F

Nucleic acid molecules encoding monoclonal antibodies specific for IL-22

Human anti-IL-32 antibodies and methods of making and using the same

Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.

Method of isolating human antibodies

Growing community of inventors

Bellinzona, Switzerland

Annalisa Macagno